DexCom reported Q2 2024 revenue of $1.004 billion, up 15% YoY, with U.S. revenue growing 19% and international revenue increasing 7%. GAAP operating income reached $158.0 million, representing a 15.7% margin. The company achieved significant strategic milestones, including the launch of Direct-to-Watch and expanded coverage for Dexcom ONE in France.The company updated its FY2024 guidance, projecting revenue of $4.00-4.05 billion with 11-13% organic growth, and maintaining its Non-GAAP Operating Margin target of approximately 20%. For Q3 2024, revenue is expected to be $975 million to $1.00 billion, representing 1-3% organic growth.DexCom announced a $750 million share repurchase program ending June 30, 2025. The company's financial position remains strong with $3.12 billion in cash, cash equivalents and marketable securities as of June 30, 2024, providing significant flexibility for production capacity expansion and market opportunities.

DexCom reported Q2 2024 revenue of $1.004 billion, up 15% YoY, with U.S. revenue growing 19% and international revenue increasing 7%. GAAP operating income reached $158.0 million, representing a 15.7% margin. The company achieved significant strategic milestones, including the launch of Direct-to-Watch and expanded coverage for Dexcom ONE in France.The company updated its FY2024 guidance, projecting revenue of $4.00-4.05 billion with 11-13% organic growth, and maintaining its Non-GAAP Operating Margin target of approximately 20%. For Q3 2024, revenue is expected to be $975 million to $1.00 billion, representing 1-3% organic growth.DexCom announced a $750 million share repurchase program ending June 30, 2025. The company's financial position remains strong with $3.12 billion in cash, cash equivalents and marketable securities as of June 30, 2024, providing significant flexibility for production capacity expansion and market opportunities.